Tag: rare_disease
-
NIH-Backed Cyclodextrin Wins FDA Approval as First Treatment for Infants With Niemann-Pick Type C
Two decades of NIH research culminate in FDA approval of cyclodextrin (Adrabetadex), the first drug shown to extend survival in infants with the rare, fatal neurological disorder Niemann-Pick Type C.
HealthScience & TechnologyPolitics and GovernmentMedical ScienceFederal GovernmentLegal Niemann-Pick Type CcyclodextrinAdrabetadexNational Institutes of HealthFDA approvalrare diseaseBeren Therapeutics